Sequenom Announces Preliminary 2012 Operational Highlights

          Sequenom Announces Preliminary 2012 Operational Highlights

PR Newswire

SAN DIEGO, Jan. 6, 2013

SAN DIEGO, Jan. 6, 2013 /PRNewswire/ --Sequenom, Inc. (NASDAQ: SQNM), a life
sciences company providing innovative diagnostic testing and genetic analysis
solutions, today announced preliminary highlights of the Company's 2012
performance and accomplishments.

Initial 2012 Performance Results (unaudited)

  oTotal revenue of approximately $89 million, growth of approximately 59
    percent year-over-year for 2012
  oDiagnostic services revenues of approximately $46 million, compared to
    $8.3 million in 2011. Diagnostic services revenues continue to be
    recorded primarily as cash is received
  oSales in the Genetic Analysis business of approximately $43 million
  oMore than 92,000 total prenatal and retinal diagnostic tests accessioned
    during the year
  oStrong increases in the adoption rate and sales of Sequenom Center for
    Molecular Medicine's (Sequenom CMM) MaterniT21 PLUS lab-developed test

       oMore than 60,000 MaterniT21 PLUS tests accessioned in 2012
       oAn annualized run rate of more than 120,000 MaterniT21 PLUS tests
         accessioned at the end of 2012
       oApproximately 56 million lives under coverage with growing number of
         payor contracts
       oContinued reimbursement as an out-of-network laboratory from large
         commercial payors

  oTotal cash, cash equivalents, and marketable securities as of December 31,
    2012 were approximately $176 million
  oCash burn of approximately $17 million for the fourth quarter of 2012

"2012 was a year of remarkable progress for Sequenom. The rapid adoption of
the Sequenom CMM's MaterniT21 PLUS by the OB/GYN physician community far
exceeded the Company's internal goal and the estimates of industry analysts.
The joint recommendation by the American College of Obstetricians and
Gynecologists (ACOG) and the Society of Maternal and Fetal Medicine (SMFM) for
the use of noninvasive prenatal tests (NIPT) such as the MaterniT21 PLUS in
high risk pregnancies provided an additional validation for this technology.
The company also exceeded the majority of its other goals as it established
Sequenom CMM as a leader in the prenatal testing market," said Harry F.
Hixson, Jr, Ph.D., Chairman and CEO of Sequenom. "We look forward to the
continued growth of the MaterniT21 PLUS LDT in 2013 and the corresponding
increase in test capacity. We plan to work with national and regional payors
to establish additional contracts facilitating the availability of the
MaterniT21 PLUS LDT to high-risk pregnant women throughout the United States."

This press release contains certain unaudited financial results for the
Company's fiscal year and fourth quarter ended December 31, 2012. These
unaudited results may change as a result of further review by the Company's
management and its independent auditors. The completion of the audit of our
financial results for 2012 could result in changes to the unaudited financial
results presented in this press release and may identify issues related to the
effectiveness of the Company's internal controls over financial reporting.

On Wednesday, January 9th, Chairman and CEO Harry F. Hixson, Jr., Ph.D, and
Ronald M. Lindsay, Ph.D., Director and EVP of Strategic Planning, will present
at the JP Morgan 31^st Annual Healthcare Conference in San Francisco, CA,
starting at 11:30 am PT (2:30 pm ET) to provide an overview of and update on
the Company.

The presentation is expected to last approximately 30 minutes and will be
webcast live through the "Investors" section of the Sequenom website at An audio replay will be available for 30 days following the
initial presentation webcast. The presentation is currently posted on the
Company's website.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to
improving healthcare through revolutionary genetic analysis solutions.
Sequenom develops innovative technology, products and diagnostic tests that
target and serve discovery and clinical research, and molecular diagnostics
markets. The company was founded in 1994 and is headquartered in San Diego,
California. Sequenom maintains a Web site at to which
Sequenom regularly posts copies of its press releases as well as additional
information about Sequenom. Interested persons can subscribe on the Sequenom
Web site to email alerts or RSS feeds that are sent automatically when
Sequenom issues press releases, files its reports with the Securities and
Exchange Commission or posts certain other information to the Web site.

About Sequenom CMM

Sequenom Center for Molecular Medicine® (Sequenom CMM), a CAP accredited and
CLIA-certified molecular diagnostics laboratory, is developing a broad range
of diagnostics with a focus on prenatal and ophthalmological diseases and
conditions. Branded under the name SensiGene™, RetnaGene™, MaterniT21 PLUS™
these genetic tests provide better patient management alternatives for
obstetricians, geneticists and maternal fetal medicine specialists. Sequenom
CMM is changing the landscape in genetic disorder diagnostics using
proprietary cutting edge technologies.

Forward-Looking Statement

Except for the historical information contained herein, the matters set forth
in this press release, including statements regarding an annualized run rate
for MaterniT21 PLUS tests accessioned, expectations of continued reimbursement
from large commercial payors, expectations of continued growth of the
MaterniT21 PLUS test in 2013 and corresponding increase in test capacity, the
Company's plans to work with national and regional payors to establish
additional contracts for test availability for pregnant women throughout the
United States, further review of financial results for the fiscal year and
quarter ended December 31, 2012 to be conducted by the Company's management
and its independent auditors, the completion of the audit of the Company's
financial results for 2012 and its potential change or impact on the unaudited
financial results presented herein and/or identification of issues related to
the effectiveness of the Company's internal controls over financial reporting,
and the Company's commitment to improving healthcare through revolutionary
genetic analysis solutions are forward-looking statements within the meaning
of the "safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995. These forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially, including
the risks and uncertainties associated with market demand for and acceptance
and use of technology and tests such as the MaterniT21 PLUS test, reliance
upon the collaborative efforts of other parties such as, without limitation,
healthcare providers, international distributors and licensees, the Company or
third parties obtaining or maintaining regulatory approvals that impact the
Company's business, government regulation particularly with respect to
diagnostic products and laboratory developed tests, publication processes, the
performance of designed product enhancements, the Company's ability to develop
and commercialize technologies and products, particularly new technologies
such as noninvasive prenatal diagnostics, laboratory developed tests, and
genetic analysis platforms, the Company's financial position, the Company's
ability to manage its existing cash resources or raise additional cash
resources, competition, intellectual property protection and intellectual
property rights of others, litigation involving the Company, and other risks
detailed from time to time in the Company's most recently filed Quarterly
Report on Form 10-Q for the quarter ended September 30, 2012 and its Annual
Report on Form 10-K for the year ended December 31, 2011, and other documents
subsequently filed with or furnished to the Securities and Exchange
Commission. These forward-looking statements are based on current information
that may change and you are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this press
release. All forward-looking statements are qualified in their entirety by
this cautionary statement, and the Company undertakes no obligation to revise
or update any forward-looking statement to reflect events or circumstances
after the issuance of this press release.


SOURCE Sequenom, Inc.

Contact: Marcy Graham, Senior Director, Investor Relations & Corp Comm,
Sequenom, Inc., +1-858-202-9028,, or Jakob Jakobsen,
Media Contact, Chandler Chicco Agency, +1-310-309-1003,
Press spacebar to pause and continue. Press esc to stop.